The association of human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2) expression with gastric cancer prognosis
Authors:
- Masataka ShimonosonoMSMasataka Shimonosono
- Takaaki ArigamiTATakaaki Arigami
- Shigehiro YanagitaSYShigehiro Yanagita
- Daisuke MatsushitaDMDaisuke Matsushita
- Yuko KijimaYKYuko Kijima
- Hiroshi KuraharaHKHiroshi Kurahara
- Yoshiaki KitaYKYoshiaki Kita
- Shinichiro MoriSMShinichiro Mori
- Ken SasakiKSKen Sasaki
- Kosei MaemuraKMKosei Maemura
Open Access
- 24 April 2018
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (31) , 22069-22078
Abstract
The association of human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2) expression with gastric cancer prognosis The association of human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2) expression with gastric cancer prognosisKeywords
This publication has 23 references indexed in Scilit:
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2017
- Comparison of the Differences in Survival Rates between the 7th and 8th Editions of the AJCC TNM Staging System for Gastric Adenocarcinoma: a Single-Institution Study of 5,507 Patients in KoreaJournal of Gastric Cancer, 2017
- HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survivalScientific Reports, 2016
- A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2Clinical Cancer Research, 2015
- Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancerAnnals of Oncology, 2014
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialThe Lancet Oncology, 2014
- HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell functionProceedings of the National Academy of Sciences, 2013
- Evolution of the B7 family: co-evolution of B7H6 and NKp30, identification of a new B7 family member, B7H7, and of B7's historical relationship with the MHCImmunogenetics, 2012
- The B7 Family and Cancer Therapy: Costimulation and CoinhibitionClinical Cancer Research, 2007
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001